Skip to main content

Table 2 Baseline characteristics of MSI-H mCRC patient cohort

From: Bayesian additional evidence for decision making under small sample uncertainty

Characteristic Chemotherapy and bevacizumab
n = 118
Chemotherapy and cetuximab
n = 7
Median age at 1 L start, years (IQR) 62 (50, 73) 65 (60, 76)
Sex, n (%) Female 66 (56) 6 (86)
  Male 52 (44) 1 (14)
Race, n (%) White 85 (72) 5 (71)
  Other 14 (12) 1 (14)
  Black/Afr. Am. 9 (7.6) 0
  Unknown 7 (5.9) 1 (14)
  Asian 3 (2.5) 0
BRAF mutation 26 (22) 3 (43)
NRAS or KRAS mutation 15 (13) 0
Chemotherapy FOLFOX 89 (75) 3 (43)
  FOLFIRI 29 (25) 4 (57)